title: SUMO, Ubiquitin, UBL Proteins: Implications For Human Diseases - Fifth International Conference.
abstract: The fifth international conference on SUMO, Ubiquitin, UBL Proteins: Implications for Human Diseases, held in Houston, included topics covering the latest advances and new targets in the field of protein modification. This conference report highlights selected presentations on the structural characterization of ubiquitination and SUMOylation machinery; the regulation of ubiquitination enzymes, including E3 ligases; the functions and mechanism of action of SUMO-targeted ubiquitin ligases (STUbLs); the regulation of gene expression by SUMO; non-degradative functions of ubiquitin and SUMO in signal transduction; mechanisms and functions of ISG15 conjugation; the interaction of pathogens with host cell SUMOylation machinery; and stabilization of the Axin protein. Investigational drugs discussed include MLN-4924 (Millennium Pharmaceuticals Inc).
authors.affiliation: University of Texas Southwestern Medical Center, Department of Molecular Biology, Dallas, TX 75390-9148, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Skaug
authors.forename: Zhijian J
authors.initials: ZJ
authors.lastname: Chen
mesh_terms: D000494:Allosteric Regulation / Q000502:physiology; D001427:Bacterial Toxins / Q000378:metabolism / Q000494:pharmacology; D003141:Communicable Diseases / Q000378:metabolism*; D003517:Cyclopentanes / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004789:Enzyme Activation / Q000502:physiology; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D005786:Gene Expression Regulation / Q000502:physiology; D006360:Heat-Shock Proteins / Q000378:metabolism / Q000494:pharmacology; D006460:Hemolysin Proteins / Q000378:metabolism / Q000494:pharmacology; D006575:Heterocyclic Compounds, 3-Ring / Q000494:pharmacology; D006801:Humans; D000075687:NEDD8 Protein; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D009687:Nuclear Proteins / Q000737:chemistry / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000502:physiology; D011743:Pyrimidines / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D025841:Small Ubiquitin-Related Modifier Proteins / Q000737:chemistry / Q000378:metabolism*; D038501:Tankyrases / Q000037:antagonists & inhibitors; D014157:Transcription Factors / Q000737:chemistry / Q000378:metabolism; D025801:Ubiquitin / Q000737:chemistry / Q000378:metabolism*; D044764:Ubiquitin-Activating Enzymes / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D044763:Ubiquitin-Conjugating Enzymes / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D044767:Ubiquitin-Protein Ligases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D054875:Ubiquitination / Q000187:drug effects; D014452:Ubiquitins / Q000235:genetics / Q000378:metabolism
chemical_list: D001427:Bacterial Toxins; D003517:Cyclopentanes; D016207:Cytokines; D004791:Enzyme Inhibitors; D006360:Heat-Shock Proteins; D006460:Hemolysin Proteins; D006575:Heterocyclic Compounds, 3-Ring; D000075687:NEDD8 Protein; C082860:NEDD8 protein, human; D009687:Nuclear Proteins; D011743:Pyrimidines; C114070:RNF4 protein, human; D025841:Small Ubiquitin-Related Modifier Proteins; D014157:Transcription Factors; D025801:Ubiquitin; D014452:Ubiquitins; C544261:XAV939; C074034:ISG15 protein, human; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D038501:Tankyrases; D044764:Ubiquitin-Activating Enzymes; C038705:hlyA protein, Listeria monocytogenes; C539933:pevonedistat